Suppan, C.
Escalation of neoadjuvant therapy in triple-negative breast cancer-balancing effectiveness and toxicities
MEMO-MAG EUR MED ONC. 2024;
Doi: 10.1007/s12254-024-00997-3
Web of ScienceFullTextFullText_MUG
With the incorporation of immune checkpoint inhibitors into the neoadjuvant treatment of patients with triple-negative breast cancer, we are confronted with a new toxicity profile, while adding significant improvement in pathologic complete response rates and event-free survival.
Find related publications in this database (Keywords)